S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)

Arcellx (ACLX) Stock Forecast, Price & News

$40.13
-0.56 (-1.38%)
(As of 06/9/2023 ET)
Compare
Today's Range
$38.79
$41.53
50-Day Range
$27.49
$46.90
52-Week Range
$13.71
$48.92
Volume
710,706 shs
Average Volume
483,126 shs
Market Capitalization
$1.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.38

Arcellx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
25.6% Upside
$50.38 Price Target
Short Interest
Bearish
22.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Arcellx in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$89.53 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.20) to ($2.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

828th out of 986 stocks

Biological Products, Except Diagnostic Industry

135th out of 163 stocks


ACLX stock logo

About Arcellx (NASDAQ:ACLX) Stock

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update
Arcellx Inc (ACLX) Receives a Buy from Stifel Nicolaus
8-K: Arcellx, Inc.
See More Headlines

ACLX Price History

ACLX Company Calendar

Last Earnings
3/29/2023
Today
6/09/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACLX
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.38
High Stock Price Forecast
$104.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+27.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-188,680,000.00
Pretax Margin
-1,058.80%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.68 per share

Miscellaneous

Free Float
45,187,000
Market Cap
$1.89 billion
Optionable
Not Optionable
Beta
-0.34

Key Executives

  • Mr. Rami Elghandour (Age 44)
    Chairman, CEO & Pres
    Comp: $803.97k
  • Mr. Neeraj P. Teotia (Age 48)
    Chief Commercial Officer
    Comp: $461.95k
  • Dr. Christopher R. Heery M.D. (Age 43)
    Chief Medical Officer
    Comp: $629.92k
  • Ms. Michelle Lim Gilson (Age 31)
    Chief Financial Officer
  • Mr. Michael Dombeck M.B.A.
    Chief Operating Officer
  • Mr. Narinderjeet Singh M.S. (Age 51)
    Chief Technical Officer
  • Mr. David Tice Ph.D. (Age 52)
    Chief Scientific Officer
  • Ms. Myesha Lacy
    VP of Investor Relations
  • Ms. Maryam Abdul-Kareem J.D.
    M.S., Gen. Counsel
  • Ms. Kate Aiken
    Chief People Officer













ACLX Stock - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings
or view top-rated stocks.

What is Arcellx's stock price forecast for 2023?

11 analysts have issued twelve-month target prices for Arcellx's stock. Their ACLX share price forecasts range from $34.00 to $104.00. On average, they anticipate the company's share price to reach $50.38 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for ACLX
or view top-rated stocks among Wall Street analysts.

How have ACLX shares performed in 2023?

Arcellx's stock was trading at $30.98 at the beginning of the year. Since then, ACLX stock has increased by 27.1% and is now trading at $39.39.
View the best growth stocks for 2023 here
.

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ACLX earnings forecast
.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) released its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.05.

When did Arcellx IPO?

(ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share.

What is Arcellx's stock symbol?

Arcellx trades on the NASDAQ under the ticker symbol "ACLX."

Who are Arcellx's major shareholders?

Arcellx's stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.00%), FMR LLC (5.61%), Suvretta Capital Management LLC (5.00%), BlackRock Inc. (4.64%), State Street Corp (3.91%) and Pictet Asset Management SA (2.15%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Rami Elghandour, Scott D Sandell and Sr One Capital Management, Llc.
View institutional ownership trends
.

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcellx's stock price today?

One share of ACLX stock can currently be purchased for approximately $39.39.

How much money does Arcellx make?

Arcellx (NASDAQ:ACLX) has a market capitalization of $1.89 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($4.34) on an earnings per share basis.

How can I contact Arcellx?

The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com.

This page (NASDAQ:ACLX) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -